Effects of FGF19 Analogue Aldafermin in Patients With Bile Acid Diarrhea: A Randomized, Placebo-Control Trial
Open Access
- 20 April 2023
- journal article
- editorial
- Published by Elsevier in Gastroenterology
- Vol. 165 (2) , 499-501.e4
Abstract
No abstract availableKeywords
Funding Information
- NGM Biopharmaceuticals
- National Institutes of Health (R01-DK115950)
- National Center for Advancing Translational Sciences (UL1-TR002377)
This publication has 15 references indexed in Scilit:
- Description of analytical method and clinical utility of measuring serum 7-alpha-hydroxy-4-cholesten-3-one (7aC4) by mass spectrometryClinical Biochemistry, 2018
- NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patientsJournal of Hepatology, 2017
- Bowel DisordersGastroenterology, 2016
- Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid DiarrheaAmerican Journal of Gastroenterology, 2016
- Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysisGut, 2015
- Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea‐predominant irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2015
- Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patientsHealth and Quality of Life Outcomes, 2013
- Effects of Chenodeoxycholate and a Bile Acid Sequestrant, Colesevelam, on Intestinal Transit and Bowel FunctionClinical Gastroenterology and Hepatology, 2010
- A New Mechanism for Bile Acid Diarrhea: Defective Feedback Inhibition of Bile Acid BiosynthesisClinical Gastroenterology and Hepatology, 2009
- Defecation frequency and timing, and stool form in the general population: a prospective study.Gut, 1992